Novartis announces six-year data of Reclast injection for postmenopausal women with osteoporosis

September 19, 2017

Reclast provides year-long bisphosphonate compliance with a single infusion. Reclast is the only yearly treatment approved to reduce the risk of fractures in areas of the body typically affected by osteoporosis, including the hip, spine and non-spine (e.g., wrist and rib). Additionally, it is also the only proven therapy to reduce new clinical fracture after a recent low trauma hip fracture.

Reclast is approved for five indications to treat a broad spectrum of osteoporosis patients, from early to advanced bone loss. These include treatment of postmenopausal osteoporosis, prevention of postmenopausal osteoporosis, increase in bone mass in men with osteoporosis, treatment and prevention of glucocorticoid-induced osteoporosis in men and women, and treatment of Paget's disease of bone in men and women.

Reclast is available in all 50 US states and is reimbursed for the treatment of osteoporosis by all Medicare Part B carriers and virtually all health insurance.

You should not take Reclast if you're on Zometa? (zoledronic acid) Injection because it contains the same active ingredient. Additionally, you should not take Reclast if you are pregnant, plan to become pregnant, you are nursing, have low blood calcium, kidney problems, or are allergic to Reclast.

It's important to drink fluids before getting Reclast to help prevent kidney problems. The most common side effects include flu-like symptoms, fever, muscle or joint pain, and headache. Tell your doctor if you have dental problems because rarely, problems with the jaw have been reported with Reclast. Discuss all medicines you are taking, including prescription and non-prescription drugs, vitamins, and herbal supplements. If you develop severe bone, joint, or muscle pain, numbness, tingling or muscle spasms, contact your doctor.

Zoledronic acid, the active ingredient in Reclast, is also available under the trade-name Zometa for use in oncology indications.

SOURCE Novartis Pharmaceuticals Corporation